International Flavors & Fragrances Inc.

- The transcript does not mention any plans for new fundraising through debt or equity. - The company emphasizes disciplined capital allocation and maintaining a net debt-to-EBITDA leverage around 2.5x. - A share buyback program was initiated in late 2025 to offset dilution, indicating use of excess cash rather than raising funds. - If there is an influx of cash from potential divestitures (such as the Food Ingredients sale), proceeds will likely be used to maintain debt leverage and for share repurchases, not new fundraising. - The company focuses on funding organic growth, bolt-on acquisitions, and ventures through existing resources. - Overall, there is no indication of current or planned debt or equity raises in the near term.

- IFF is investing for the future in innovation, commercial, and supply chain capabilities as well as in customer partnerships that matter most (Page 4). - The company maintains a disciplined capital allocation strategy, investing in organic growth initiatives with high return profiles and pursuing bolt-on acquisitions and ventures that create strong shareholder value (Page 7). - Recent focus includes strengthening the R&D pipeline, especially in specialty fragrance ingredients, naturals, synthetics, and biotech molecules (Page 7). - Capital expenditures year-to-date are $165 million, roughly 6% of sales (Page 3). - IFF is also investing in productivity initiatives to offset inflationary pressures and improve profitability (Page 6 and 11). - The ongoing divestiture of the Food Ingredients business is a strategic move to optimize the portfolio (Pages 4, 9, 10). - Overall, investments are geared toward accelerating commercial and innovation pipelines and driving long-term value creation (Page 4).

- The company expects solid top-line growth driven by volume growth across all segments, supported by strong innovation and commercial pipelines. - Health & Biosciences segment shows mid-single-digit growth, especially in Animal Nutrition and Food Biosciences, with volume growth driving sales. - Taste segment performance is solid, growing ahead of the market with mid-single-digit growth in Greater Asia and good commercial/innovation pipelines. - Consumer Fragrance is expected to improve in the second half of 2026 and into 2027 with a strong innovation pipeline. - Food Ingredients segment turnaround continues with return to top-line growth expected for the full year. - Growth is anticipated to accelerate in the back half of 2026, with stronger momentum into 2027, particularly in Health & Biosciences and Consumer Fragrance. - Continued volume-led growth is expected, with no material prebuy impact seen in Q1. - Overall, confident in meeting full-year 2026 guidance despite macroeconomic challenges.

- The company expects a modest overall price increase in the near term, driven mainly by logistics and energy cost surcharges, with further focus on raw material costs into late 2026 and 2027. - EBITDA is expected to grow 3% to 8% for full-year 2026, with solid margin expansion despite inflationary pressures. - Pricing actions to offset inflation are underway, full effect anticipated post-Q2 2026. - Productivity remains strong and could be accelerated if pricing actions are insufficient to cover cost pressures. - The Food Ingredients segment is performing well with EBITDA margin growth from 9% in 2023 to an expected over 14% in 2026. - Free cash flow is targeted to improve meaningfully in 2026 driven by profitability, working capital, lower interest expense, and lower incentive payouts. - Innovation and commercial pipelines are expected to strengthen growth starting in the back half of 2026 and accelerating into 2027. - Long-term focus on margin improvement through innovation and productivity rather than just pricing.

- The company reports a strong commercial and innovation pipeline across its divisions. - In the Taste division, commercial pipelines are robust and expected to continue delivering growth. - The Consumer Fragrance segment has a very strong team and commercial pipeline, with improvements expected in the second half of 2026 and into 2027. - Health & Biosciences pipelines are also strong, with progress expected to manifest in numbers in the latter half of 2026 and accelerating into 2027. - Despite some temporary challenges in Fine Fragrance due to the Middle East situation, long-term order and demand pipelines remain solid. - The company emphasizes strong customer partnerships and ongoing innovation as drivers of orderbook strength. - Overall, the company expresses confidence in the pipelines fueling future growth, supporting the reaffirmed full-year 2026 guidance.